Safety assessment of terazosin in thetreatment of patients with symptomatic benign prostatic hyperplasia

A combined analysis

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Objectives: This study reviews and assesses the safety of terazosin for thetreatment of symptomatic benign prostatic hyperplasia (BPH). Methods.: Six placebo-controlled trials (including two unpublished series) involving 996patients provide the database for this evaluation. Six hundred thirty-six patients received terazosin from 1 to 20 mg daily for a total of 229 patient-years of exposure to terazosin. The most common final dose of terazosin was 10 mg once daily. Results: Side effects were generally mild or moderate in severity and resolved following cessation of therapy. Side effects resulted in premature withdrawal in 9% of terazosin-treated patients and 7% of placebo-treated patients (difference not significant). Dizziness (2.0%) and headache (1.1 %) were the most common symptoms leading to premature withdrawal from the studies. Although postural symptoms and dizziness were slightly more common in those terazosin-treated patients 65 or more years old compared with patients less than 65 years old, this difference was not statistically significant. Only 4 of the 636 patients (0.6%) had syncopal episodes; 2 of these occurred at initiation of terazosin therapy or at dose escalation. Minimal reductions in blood pressure were observed in normotensive patients and patients with hypertension controlled by concomitant medication, whereas patients with untreated hypertension had substantial decreases in both systolic and diastolic blood pressures. Statistically significant increases in high density lipoprotein to cholesterol ratio and reductions in total cholesterol, low density lipoprotein, and triglycerides were also seen. Conclusions.: This combined analysis suggests that terazosin can be safely administered to both normotensive and hypertensive patients with symptomatic BPH.

Original languageEnglish (US)
Pages (from-to)46-51
Number of pages6
JournalUrology
Volume44
Issue number1
DOIs
StatePublished - 1994
Externally publishedYes

Fingerprint

Terazosin
Prostatic Hyperplasia
Safety
Dizziness
Blood Pressure
Placebos
Hypertension

ASJC Scopus subject areas

  • Urology

Cite this

@article{530023ed250b480a8bc912289215fc65,
title = "Safety assessment of terazosin in thetreatment of patients with symptomatic benign prostatic hyperplasia: A combined analysis",
abstract = "Objectives: This study reviews and assesses the safety of terazosin for thetreatment of symptomatic benign prostatic hyperplasia (BPH). Methods.: Six placebo-controlled trials (including two unpublished series) involving 996patients provide the database for this evaluation. Six hundred thirty-six patients received terazosin from 1 to 20 mg daily for a total of 229 patient-years of exposure to terazosin. The most common final dose of terazosin was 10 mg once daily. Results: Side effects were generally mild or moderate in severity and resolved following cessation of therapy. Side effects resulted in premature withdrawal in 9{\%} of terazosin-treated patients and 7{\%} of placebo-treated patients (difference not significant). Dizziness (2.0{\%}) and headache (1.1 {\%}) were the most common symptoms leading to premature withdrawal from the studies. Although postural symptoms and dizziness were slightly more common in those terazosin-treated patients 65 or more years old compared with patients less than 65 years old, this difference was not statistically significant. Only 4 of the 636 patients (0.6{\%}) had syncopal episodes; 2 of these occurred at initiation of terazosin therapy or at dose escalation. Minimal reductions in blood pressure were observed in normotensive patients and patients with hypertension controlled by concomitant medication, whereas patients with untreated hypertension had substantial decreases in both systolic and diastolic blood pressures. Statistically significant increases in high density lipoprotein to cholesterol ratio and reductions in total cholesterol, low density lipoprotein, and triglycerides were also seen. Conclusions.: This combined analysis suggests that terazosin can be safely administered to both normotensive and hypertensive patients with symptomatic BPH.",
author = "Lowe, {Franklin C.}",
year = "1994",
doi = "10.1016/S0090-4295(94)80008-1",
language = "English (US)",
volume = "44",
pages = "46--51",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Safety assessment of terazosin in thetreatment of patients with symptomatic benign prostatic hyperplasia

T2 - A combined analysis

AU - Lowe, Franklin C.

PY - 1994

Y1 - 1994

N2 - Objectives: This study reviews and assesses the safety of terazosin for thetreatment of symptomatic benign prostatic hyperplasia (BPH). Methods.: Six placebo-controlled trials (including two unpublished series) involving 996patients provide the database for this evaluation. Six hundred thirty-six patients received terazosin from 1 to 20 mg daily for a total of 229 patient-years of exposure to terazosin. The most common final dose of terazosin was 10 mg once daily. Results: Side effects were generally mild or moderate in severity and resolved following cessation of therapy. Side effects resulted in premature withdrawal in 9% of terazosin-treated patients and 7% of placebo-treated patients (difference not significant). Dizziness (2.0%) and headache (1.1 %) were the most common symptoms leading to premature withdrawal from the studies. Although postural symptoms and dizziness were slightly more common in those terazosin-treated patients 65 or more years old compared with patients less than 65 years old, this difference was not statistically significant. Only 4 of the 636 patients (0.6%) had syncopal episodes; 2 of these occurred at initiation of terazosin therapy or at dose escalation. Minimal reductions in blood pressure were observed in normotensive patients and patients with hypertension controlled by concomitant medication, whereas patients with untreated hypertension had substantial decreases in both systolic and diastolic blood pressures. Statistically significant increases in high density lipoprotein to cholesterol ratio and reductions in total cholesterol, low density lipoprotein, and triglycerides were also seen. Conclusions.: This combined analysis suggests that terazosin can be safely administered to both normotensive and hypertensive patients with symptomatic BPH.

AB - Objectives: This study reviews and assesses the safety of terazosin for thetreatment of symptomatic benign prostatic hyperplasia (BPH). Methods.: Six placebo-controlled trials (including two unpublished series) involving 996patients provide the database for this evaluation. Six hundred thirty-six patients received terazosin from 1 to 20 mg daily for a total of 229 patient-years of exposure to terazosin. The most common final dose of terazosin was 10 mg once daily. Results: Side effects were generally mild or moderate in severity and resolved following cessation of therapy. Side effects resulted in premature withdrawal in 9% of terazosin-treated patients and 7% of placebo-treated patients (difference not significant). Dizziness (2.0%) and headache (1.1 %) were the most common symptoms leading to premature withdrawal from the studies. Although postural symptoms and dizziness were slightly more common in those terazosin-treated patients 65 or more years old compared with patients less than 65 years old, this difference was not statistically significant. Only 4 of the 636 patients (0.6%) had syncopal episodes; 2 of these occurred at initiation of terazosin therapy or at dose escalation. Minimal reductions in blood pressure were observed in normotensive patients and patients with hypertension controlled by concomitant medication, whereas patients with untreated hypertension had substantial decreases in both systolic and diastolic blood pressures. Statistically significant increases in high density lipoprotein to cholesterol ratio and reductions in total cholesterol, low density lipoprotein, and triglycerides were also seen. Conclusions.: This combined analysis suggests that terazosin can be safely administered to both normotensive and hypertensive patients with symptomatic BPH.

UR - http://www.scopus.com/inward/record.url?scp=0028364522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028364522&partnerID=8YFLogxK

U2 - 10.1016/S0090-4295(94)80008-1

DO - 10.1016/S0090-4295(94)80008-1

M3 - Article

VL - 44

SP - 46

EP - 51

JO - Urology

JF - Urology

SN - 0090-4295

IS - 1

ER -